CancerNetwork® sat down with Salma Jabbour, MD, of Rutgers Cancer Institute, at 2021 ASCO to talk about what she believed was the most interesting and impactful study to come out of the meeting.
Salma K. Jabbour, MD
Advertisement
Articles by Salma K. Jabbour, MD
Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed the adverse events associated with the use of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey spoke about the possible implications of the KEYNOTE-799 study findings.
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed updated results from the study of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
The KEYNOTE-799 study is evaluating pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer
ByWilliam Small, Jr, MD,John P. Hayes, MD,W. Warren Suh, MD, MPH,May Abdel-Wahab, MD, PhD,Ross A. Abrams, MD,Nilofer Azad, MD,Prajnan Das, MD, MS, MPH,Jadranka Dragovic, MD,Karyn A. Goodman, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Percy Lee, MD,Timothy M. Pawlik, MD,Joseph M. Herman, MD, MSc
These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.
ACR Appropriateness Criteria® Resectable Stomach Cancer
ByParima Daroui, MD, PhD,Salma K. Jabbour, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Karyn A. Goodman, MD,Theodore S. Hong, MD,William E. Jones III, MD,Harmeet Kaur, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Timothy M. Pawlik, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD, MPH
For resectable gastric cancer, perioperative chemotherapy or adjuvant chemoradiation with chemotherapy are standards of care. The decision making for adjuvant therapeutic management can depend on the stage of the cancer, lymph node positivity, and extent of surgical resection.
ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation
ByKaryn A. Goodman, MD,Sarah A. Milgrom, MD,Joseph M. Herman, MD, MSc,May Abdel-Wahab, MD, PhD,Nilofer Azad, MD,A. William Blackstock, MD,Prajnan Das, MD,Theodore S. Hong, MD,Salma K. Jabbour, MD,William E. Jones III, MD,Andre A. Konski, MD, MBA, MA,Albert C. Koong, MD, PhD,Rachit Kumar, MD,Miguel Rodriguez-Bigas, MD,William Small, Jr, MD,Charles R. Thomas, Jr, MD,W. Warren Suh, MD
The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.
Advertisement
Latest Updated Articles
Salma Jabbour, MD, on Future Trials in Stage III NSCLCPublished: July 1st 2021 | Updated:
- ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation
Published: October 15th 2014 | Updated:
- ACR Appropriateness Criteria® Resectable Stomach Cancer
Published: August 15th 2015 | Updated:
- ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer
Published: July 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
3
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer
4
Tarlatamab May Offer New SOC for Relapsed ES-SCLC With Brain Metastases
5
